Drug
111in Ipn01087 Low Dose
111in Ipn01087 Low Dose: highest development phase Phase 1, developed by Ipsen. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Ipsen
Trials
| Drug | Phase | Indication |
|---|---|---|
| 111In-IPN01087 Low dose NCT04632199 | Phase 1 | Pancreatic Ductal Adenocarcinoma |
Latest
No recent events.
Follow 111in Ipn01087 Low Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.